Literature DB >> 21740683

High-dose rifampicin: how do we proceed?

M J Boeree, G Plemper van Balen, R A Aarnoutse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21740683     DOI： 10.5588/ijtld.11.0198

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  6 in total

1.  Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.

Authors:  Kelly E Dooley; Radojka M Savic; Jeong-Gun Park; Yoninah Cramer; Richard Hafner; Evelyn Hogg; Jennifer Janik; Mark A Marzinke; Kristine Patterson; Constance A Benson; Laura Hovind; Susan E Dorman; David W Haas
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

2.  Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.

Authors:  Teresa L Parsons; Mark A Marzinke; Thuy Hoang; Erin Bliven-Sizemore; Marc Weiner; William R Mac Kenzie; Susan E Dorman; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

Review 3.  Pipeline of drugs for related diseases: tuberculosis.

Authors:  Kelly E Dooley; Eric L Nuermberger; Andreas H Diacon
Journal:  Curr Opin HIV AIDS       Date:  2013-11       Impact factor: 4.283

4.  In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.

Authors:  Elsje Pienaar; Véronique Dartois; Jennifer J Linderman; Denise E Kirschner
Journal:  BMC Syst Biol       Date:  2015-11-14

5.  Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.

Authors:  Elsje Pienaar; Jennifer J Linderman; Denise E Kirschner
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

6.  Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.

Authors:  R M Savic; R Ruslami; J E Hibma; A Hesseling; G Ramachandran; A R Ganiem; S Swaminathan; H McIlleron; A Gupta; K Thakur; R van Crevel; R Aarnoutse; K E Dooley
Journal:  Clin Pharmacol Ther       Date:  2015-10-22       Impact factor: 6.875
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.